Authors
Latest:
Levantinib in the Management of Differentiated Thyroid CancerTherapy that targets angiogenesis has been extensively investigated in differentiated thyroid cancer (DTC) and has demonstrated significant antitumor activity.
Latest:
Clinical Outcomes for the Treatment of Pembrolizumab in Patients With Advanced Gastric CancerYung-Jue Bang, MD, PhD, professor of medical oncology, College of Medicine, Seoul National University, president, Biomedical Research Institute, Seoul National University Hospital, discusses the clinical results for the treatment of pembrolizumab in patients with advanced gastric cancer.
Latest:
Molecular Testing Helps Diagnose Low-Risk Thyroid CancerYuri E. Nikiforov, MD, PhD, discusses improvements in diagnosis of thyroid cancer including the classification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
Latest:
The Impacts of Chemotherapy Versus Immunotherapy in MelanomaYvonne Saenger, MD, director, melanoma immunotherapy, Columbia University Medical Center, discusses the impacts of chemotherapy and immunotherapy in melanoma.
Latest:
Questions to Still be Answered in MyelofibrosisZeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses questions that still need to be answered in the myelofibrosis field.
Latest:
EGFR Exon 20–Positive NSCLC: Future Directions in CareBefore closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.
Latest:
First-Line Durvalumab Betters Survival in Advanced Endometrial CancerFindings from the DUO-E study support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.
Latest:
Recent Progress and Unmet Needs in NSCLCDr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.
Latest:
Shift to Value-Based Care Brings New Desires for EHR CapabilitiesA survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.
Latest:
Cervical Cancer Awareness Month: Challenges of Reaching At-Risk PopulationsDennis Scribner, Jr, MD, discusses the challenges for reaching patients who are at the greatest risk of developing cervical cancer.
Latest:
When to Use Targeted Therapy for Iodine-Refractory Thyroid CancerKrzysztof J. Misiukiewicz, MD, discusses when targeted therapy may be used for patients with NTRK-positive thyroid cancer.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Briquilimab Combination is Safe in MDS/AML Undergoing AlloHCTLori Muffly, MD, discusses findings a sub-analysis of a phase 1 study investigating briquilimab with low-dose total body radiation and fludarabine.
Latest:
Active Research on Uproleselan in Acute Myeloid LeukemiaBrian A. Jonas, MD, discusses studies investigating the use of uproleselan for the treatment of patients with acute myeloid leukemia.
Latest:
Study Investigates Hydroxychloroquine and Itraconazole in Ovarian CancerAinhoa Madariaga, MD, discusses the data from the phase 1/2 HYDRA-01 trial looking at hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.
Latest:
Future Treatment Approaches for HCCClosing out their discussion on the management of hepatocellular carcinoma, panelists discuss future novel therapies that may impact the treatment landscape.
Latest:
Management of Adverse Events Related to Pacritinib in MyelofibrosisAshwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.
Latest:
Novel Delivery Systems, Unique Pairings Explored With Oncolytic VirusesOncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.
Latest:
Safety/Efficacy Findings Support Cabozantinib in RAI-Refractory DTCFrancis P. Worden, MD, reviews the progression-free survival data and safety findings from the phase 3 COSMIC-311 study which evaluated treatment with cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer.
Latest:
Buttin Reviews Results From PAOLA-1 in Ovarian CancerBarbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.
Latest:
Treatment Landscape for Vulvar/Vaginal MelanomaAnnelise Wilhite, MD, explains what current treatment options look like for patients with vulvar/vaginal melanoma.
Latest:
Rusfertide May Reduce Need for Therapeutic Phlebotomy in Polycythemia VeraYelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide in patients with chronic polycythemia vera.
Latest:
Lutetium-PSMA-617 and Novel Agents in Prostate CancerOncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Latest:
Belumosudil Shows Sustained Efficacy and Safety for Chronic GVHDStephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.
Latest:
Evaluating Current Treatment Options for Small Cell Lung CancerDr Ticiana Leal, MD, highlights the approvals of new regiments in small cell lung cancer. However, she discusses the struggles physicians currently face, such as identifying predictive biomarkers used to select patients who may respond well to new treatment regiments.
Latest:
Evaluating HSCT Refusal Trends Among Patients With Multiple MyelomaChakra Chaulagain, MD, discusses the context of an analysis which assessed autologous hematopoietic stem cell transplantation refusal rates among patients with multiple myeloma.
Latest:
Future Treatments in Ovarian CancerAn expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.
